Bimekizumab is the first and only IL-17A and IL-17F inhibitor approved in the European Union for active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA). Approval in PsA is supported by two phase 3 studies where bimekizumab showed improvements vs. placebo in...
Pharma Info: UCB receives new EC approvals for BIMZELX®▼(bimekizumab) for the treatment of PsA and axSpA
